Medical device company Contraline became the first to implant a hydrogel-based male contraceptive gel into humans in a clinical trial. Implanted during a noninvasive 10-minute office procedure, the gel promises to block the flow of sperm to the vas deferens. If proven safe and effective, it could become the first nonhormonal, reversible contraceptive for men on the market.
Some ethicists and advocates say it represents a double standard, citing evidence that female contraception also may be related to depression and other side effects. They argue men are being protected from the same unpleasant consequences that women are forced to accept.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
It’s not quite as simple or noninvasive as swallowing a pill, but a new form of male birth control is on target to begin human clinical trials next year, according to its developers. It’s called Vasalgel, and it’s a non-hormonal contraceptive that’s similar to a vasectomy, except without any cutting involved. Instead, the technique involves […]
How much leeway do employers and insurers have in deciding whether they’ll cover contraceptives without charge and in determining which methods make the cut? Not much, as it turns out, but that hasn’t stopped some from trying. Kaiser Health News readers still write in regularly describing battles they’re waging to get the birth control coverage […]
Medicaid patients in Illinois could gain increased access to contraception under policy changes proposed Wednesday by the Department of Healthcare and Family Services. Health care providers would receive more money for providing vasectomies to men and birth control to women under the proposal, which also includes a possible new referral requirement for Roman Catholic providers […]
The Supreme Court’s opinion Monday holding that some for-profit firms do not have to provide women the contraceptive coverage required under the Affordable Care Act if they have religious objections addressed only half of the ongoing legal battle over the birth control mandate. But those on both sides of the issue think the court’s majority […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
One of the most watched cases before the Supreme Court this term will may turn on the question of religious freedom. But it will also likely determine how women will be able to access a key provision of the Affordable Care Act – one seeking to guarantee no-cost prescription contraception in most health insurance plans. […]